The Medical Letter on Drugs and Therapeutics
PPIs and Fracture Risk
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Use of proton pump inhibitors (PPIs) to treat gastroesophageal reflux disease (GERD) has been associated with an increase in the risk of fractures. The FDA now requires that the labels of all prescription PPIs include a warning about an increased risk of fractures with long-term use.

CLINICAL STUDIES — A meta-analysis of 11 observational studies found that use of PPIs was associated with a modest increase in hip, spine and any-site fractures. The risk of hip fracture among patients taking a PPI was higher than in patients with a similar medical history who were not taking a PPI (RR 1.30, 95% CI 1.19-1.43). Fracture risk was similar with short-term (<1 year) and longer use.1

A prospective study that followed a cohort of 9,423 Canadian patients for 10 years found, after controlling for multiple risk factors, an association between PPI use and a shorter time to a first ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: PPIs and Fracture Risk
Article code: 1410d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian